Earl Rubin

Earl Rubin, MD is an Associate Professor in the Department of Pediatrics at McGill University's Faculty of Medicine and Health Sciences, and serves as an Associate Investigator at the Research Institute of the McGill University Health Centre (RI-MUHC). He specializes in the Division of Infectious Diseases at the McGill University Health Centre (MUHC), where his clinical and research activities focus on pediatric infectious diseases with particular expertise in vaccine development and clinical trials.

Dr. Rubin's primary research interest centers on industry-sponsored vaccine trials, with numerous publications spanning vaccine safety, immunogenicity, and development across various pediatric populations. His work particularly focuses on combination vaccines, hexavalent formulations, and pneumococcal conjugate vaccines. Beyond vaccine research, his scholarly contributions extend to significant public health issues including Ebola response, Zika virus implications, tuberculosis prevention challenges, and commentary on predatory academic publishing practices.

Analysis of his publication record reveals a clear trajectory from earlier work in cancer therapeutics (particularly tubulin-targeting agents) to his current focus on infectious disease management and vaccine development. His more recent publications (2025) appear as commentaries in high-impact journals like the New England Journal of Medicine, addressing contemporary health policy challenges, while his earlier work includes detailed clinical trials on pediatric vaccines and reviews on cancer therapeutics.

Dr. Rubin has contributed significantly to understanding infectious disease management in vulnerable populations, including premature infants with invasive candidiasis and children in global health crisis situations. His collaborative work demonstrates engagement with international research teams across North America addressing critical issues in pediatric infectious disease management and vaccine implementation.